NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Medical Devices · USD

PAVmed Inc. (PAVM) Stock Analysis

PAVmed Inc. (PAVM) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

PAVM

$2.10

−$0.13 (−6.05%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PAVM with… →

PAVM Key Statistics

As of Oct 21, 2026
Trading
Open
$2.20
Previous Close
$2.23
Day's Range
2.09–2.20
52-Week Range
2.09–28.44
Volume
3.68K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.70
Valuation
Market Cap
$16.75M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
149.57
EPS (ttm)Profit attributable to each share over the last twelve months.
−14.20
Financials (FY)
Revenue (FY)
$71.00K−97.63%
Net Income (FY)
$401.00K−98.99%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.00M
1-Year Return
−85.45%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
29.96K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, PAVM closed at $2.10, −85.45% over 1 year.

PAVmed Inc. (PAVM) has a market capitalization of $16.75M.

In fiscal 2025, PAVM reported revenue of $71.00K.

PAVM Stock Return by Calendar Year

PAVmed Inc. (PAVM) 10-year return: what $10,000 became

1 year
$10,000 $1,455
−85.45%
5 years
$10,000 $8
−99.92%
10 years
$10,000 $4
−99.96%

If you had invested $10,000 in PAVmed Inc. (PAVM) 10 years ago, at the close on October 21, 2016, it would have been worth $4 at the close on October 21, 2026: −99.96% in total, −54.35% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−68.40%
2025−64.81%
2024−84.76%
2023−42.78%
2022−80.49%
2021+16.04%
2020+76.67%
2019+24.74%
2018−57.90%
2017−66.88%
2016 (partial year)−52.41%

As of October 21, 2026.

PAVM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$71.00K$401.00K564.8%
2024$3.00M$39.79M1,328.6%
2023$2.45M−$64.18M−2,617.3%
2022$377.00K−$88.98M−23,602.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$71.00K−$147.00K−$21.39M$401.00K564.8%
2024$3.00M−$1.85M−$44.38M$39.79M1,328.6%
2023$2.45M−$3.97M−$68.80M−$64.18M−2,617.3%
2022$377.00K−$3.24M−$91.09M−$88.98M−23,602.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PAVM Valuation vs Medical Devices Median

Median of 145 stocks
MetricPAVMMedical Devices medianvs median
P/S ratio149.572.5359.1x the median

Medians across 145 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

PAVmed Inc. (PAVM) is capitalised at $16.75M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 41.

The most recent close on file for PAVM is $2.10, dated October 21, 2026. That is −$0.13 (−6.05%) against the previous close. The 52-week range on file runs from $2.09 to $28.44. The latest close sits 0.48% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $71.00K. That is −97.63% against the prior fiscal year, when revenue was $3.00M. The same year closed with net income of $401.00K. That is −98.99% against the prior fiscal year. Earnings per share on a trailing basis come to −14.2.

Across the 4 fiscal years on file, revenue moves from $377.00K in 2022 to $71.00K in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 149.57. On price-to-sales that is 59.1 times the Medical Devices median of 2.53. 145 Medical Devices companies report these metrics, and the medians quoted come from that group.

The trailing one-year total return is −85.45%. Across 10 years the annualized return works out at −54.35%. The reported beta is 0.7. Daily returns over the trailing 10 years annualize to a volatility of 98.68%.

Growth & Income

The record shows no dividend for PAVM.

Across the complete calendar years on file, 2020 returned +76.67% and 2024 returned −84.76%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the total return is −68.40% year to date.

Peer Comparison

PAVmed Inc. (PAVM) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
PAVmed Inc. PAVM $16.75M —
Abbott Laboratories ABT $173.92B 32.4
Medtronic plc. MDT $119.00B 22.9
Stryker Corporation SYK $114.15B 30.8

The Medical Devices industry average P/E ratio is 27.1x. PAVmed Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$173.92B

 MDT

Medtronic plc.

$119.00B

 SYK

Stryker Corporation

$114.15B

 BSX

Boston Scientific Corporation

$64.33B

 EW

Edwards Lifesciences Corporation

$50.95B

 GEHC

GE HealthCare Technologies Inc.

$31.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About PAVmed Inc.

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Visit website →